Abstract: An organic light emitting diode (OLED) with a brightness enhancer. The OLED comprises a substrate having a first surface and a second surface oppositely. An anode electrode is disposed on the first surface of the substrate. An organic light emitting layer is disposed on the anode electrode. A cathode electrode is disposed on the organic light emitting layer. A brightness enhancer is disposed on the second surface of the substrate.
Type:
Application
Filed:
August 16, 2005
Publication date:
July 6, 2006
Applicant:
Industrial Technology Research Institute
Abstract: A signal detection method and apparatus in a receiver in a MIMO mobile communication system. The receiver orders symbol combinations transmittable from a transmitter in an ascending order of the difference between the symbol combinations and transmit symbols produced by eliminating inter-symbol interference from a received signal, initializes a symbol combination with the minimum difference to an ML solution, calculates the distance between a first symbol combination and the transmit symbols and the cost of a second symbol combination, detects a symbol combination having a distance to the transmit symbols equal to the distance between the first symbol combination and the transmit symbols, and having a minimum distance, and decides the first symbol combination as the ML solution if the minimum distance exceeds the distance between the first symbol combination and the transmit symbols.
Type:
Application
Filed:
January 3, 2006
Publication date:
July 6, 2006
Applicants:
Samsung Electronics Co., Ltd., Korea Advanced Institute Of Science And Technology
Inventors:
Jong-Hyung Kwun, Chan-Soo Hwang, Kyung-Chun Lee, Joo-Hwan Chun
Abstract: A compensating circuit for compensating the terminal voltage on the armature in a sensorless type DC brushless motor apparatus is described. The driving circuit of the motor apparatus outputs a three-phase power, and each phase is connected with a compensating circuit. The compensating circuit has a reference voltage, a resistance device, a diode device, a differential amplifier and a processor. The two terminals of the resistance device are respectively connected to the reference voltage and the anode of the diode device. The cathode of the diode device is connected to an output of the three-phase power supply. The two input terminals of the differential amplifier are respectively connected to the two terminals of the resistance device. The processor accepts the signal output from the differential amplifier and then calculates and outputs a compensating voltage.
Type:
Application
Filed:
December 27, 2005
Publication date:
July 6, 2006
Applicant:
INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
Abstract: A micro droplet controlling apparatus. A dielectric layer is disposed overlying a substrate. A first electrode and a second electrode are disposed in the dielectric layer, wherein the first electrode is isolated from the second electrode, and the first and second electrodes are disposed at different positions. A micro droplet is disposed overlying the dielectric layer, wherein the first electrode and the second electrode are applied with voltage to generate a driving force to move the micro droplet.
Type:
Application
Filed:
December 28, 2005
Publication date:
July 6, 2006
Applicant:
INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
Abstract: The present invention relates generally to cancer therapy and cancer diagnostics and to agents useful therefor. More particularly, the present invention provides a novel tumorigenesis-related phosphoprotein and a nucleic acid molecule encoding same. The present invention also provides diagnostic agents to detect the presence or absence of the tumorigenesis-related phosphoprotein or the presence or absence of an expressible tumorigenesis-related gene encoding the phosphoprotein. Such diagnostic agents are useful in determining the likelihood of development of a tumor in a vertebrate animal such as mammal and, in particular, a human. The diagnostic agents provided by the present invention may be used inter alia in screening and/or predicting the likelihood of development of neoplastic diseases such as but not limited to mammary cancer.
Type:
Application
Filed:
December 12, 2003
Publication date:
July 6, 2006
Applicant:
The Walter and Eliza Hall Institute of Medical Res
Inventors:
Monilola Olayioye, Jane Visvader, Geoffrey Lindeman, Peter Hoffmann, Thomas Pomorski
Abstract: The invention provides novel single stage competitive inhibitors of plasmin from the Australian brown snake Pseudonaja textilis textilis. The invention also features polynucleotides and polynucleotide homologues encoding these inhibitors. Pharmaceutical compositions containing the plasmin inhibitors of the invention are also disclosed as well as methods useful for treatment of blood loss.
Type:
Grant
Filed:
May 7, 1999
Date of Patent:
July 4, 2006
Assignees:
The University of Queensland, National Institute of Biological Standards and Control
Inventors:
Pantaleone Paul Masci, Martin Francis Lavin, Patrick Joseph Gaffney
Abstract: Physical implementation of the switching fabric of a massive broadband switching network constructed from recursive 2-stage interconnection. The recursive 2-stage construction is realized through a hierarchical levels of implementation, including inside-chip implementation, PCB implementation, orthogonal packaging, interface-board packaging and fiber-array packaging. Smaller switches resulted from lower levels can be employed as the switching elements in the construction of a larger switch at a higher level of implementation. Such a hierarchical levels of implementation provides great flexibility and scalability in the physical realization of switching fabric and hence yields indefinitely large-scaled switches.
Type:
Grant
Filed:
June 15, 2001
Date of Patent:
July 4, 2006
Assignee:
Industrial Technology Research Institute
Abstract: Camptothecin analogs having an E-ring ketone are effective anti tumor compounds. These compounds inhibit the enzyme topoisomerase I and may alkylate DNA of the associated topoisomerase I DNA cleavable complex.
Type:
Grant
Filed:
June 30, 2003
Date of Patent:
July 4, 2006
Assignee:
Research Triangle Institute
Inventors:
Michael A. Wall, Mansukh C. Wani, Govindarajan Manikumar, Monroe E. Wall
Abstract: The present invention provides novel androgen regulated nucleic acid molecules. Related polypeptides and diagnostic methods also are provided.
Abstract: The present invention relates to a method of determining a quasi-phase matching efficiency in a periodically poled structure of an optical waveguide, a periodically poled structure of an optical waveguide, and an optical waveguide using the same. It is possible to effectively perform a quasi-phase matching when a width of periodic electrodes is shorter than a coherence length generally used as ½ of a quasi-phase matching period.
Type:
Grant
Filed:
July 12, 2004
Date of Patent:
July 4, 2006
Assignee:
Electronics and Telecommunications Research Institute
Abstract: The present invention provides a sugar-modified liposome having a sugar chain bonded to its membrane surface, preferably through a linker protein, and having excellent absorption qualities, particularly in the intestine. The molecular structure and quantity of the sugar chain is selectively varied to allow the liposome to be delivered in a targeted manner to selected cells and tissues. The liposome is applicable to medicinal drugs, cosmetics and other various products in the medical/pharmaceutical fields, and it is especially useful in a therapeutic drug delivery system that recognizes target cells and tissues, such as cancer cells, and in the delivery of drugs or genes locally to a selected region, or in a diagnostic cell/tissue sensing probe.
Type:
Grant
Filed:
January 29, 2003
Date of Patent:
July 4, 2006
Assignee:
National Institute of Advanced Industrial Science and Technology
Abstract: A method for rapid, fully automatic, two-dimensional (2-D) and three-dimensional (3-D) tracing of line-structure images, such as images of neurons produced by fluorescence confocal microscopy. A method of recursively following the line-structure topology, guided by the correlation response of a set of 4×N2 directional kernels in the 3-D case, and a set of 2×N directional kernels in the 2-D case, is presented. These kernels are derived based on a generalized cylinder model of the line-structures. The automatic tracing method includes a protocol for determining the ends of line-structures.
Type:
Grant
Filed:
January 28, 2002
Date of Patent:
July 4, 2006
Assignee:
Rensselaer Polytechnic Institute
Inventors:
Khalid Al-Kofahi, Badrinath Roysam, James N. Turner
Abstract: Described herein are genes shown to be essential for programmed cell death in C. elegans, their encoded products (RNA and polypeptides), antibodies directed against the encoded polypeptides; probes for identifying structurally related genes and bioassays for identifying functionally related cell death genes from various organisms; methods and agents for altering (increasing or decreasing) the activity of the cell death-genes and, thus, of altering cell death; and uses therefor. Specifically, two genes shown to be essential for almost all of the cell deaths which occur in the development of C. elegans, referred to as ced-3 and ced-4, have been cloned, sequenced and characterized.
Type:
Grant
Filed:
May 24, 2000
Date of Patent:
July 4, 2006
Assignee:
Massachusetts Institute of Technology
Inventors:
H. Robert Horvitz, Junying Yuan, Shai Shaham
Abstract: Devices are provided for the controlled release of drug or other molecules. The devices include (1) a substrate, which optionally includes two or more substrate portions bonded together, (2) at least two reservoirs in the substrate, (3) a release system disposed in the reservoirs that includes the molecules for release and optionally a matrix material, and (4) active or passive means for controlling release of the molecules from the reservoirs. In one embodiment, a reservoir cap is positioned on, or within a portion of, the reservoir and over the molecules, so that the molecules are controllably released from the device by diffusion through or upon disintegration of the reservoir cap.
Type:
Grant
Filed:
September 19, 2000
Date of Patent:
July 4, 2006
Assignee:
Massachusetts Institute of Technology
Inventors:
John T. Santini, Jr., Michael J. Cima, Robert S. Langer
Abstract: Multiple myeloma and other hematologic tumors and/or malignancies can be treated by administration of a G1 and/or S phase drug, which is preferably ?-lapachone, or a derivative or analog thereof, combined with a G2/M phase drug such as a taxane derivative, which is advantageously paclitaxel. This combination of the G1 and/or S phase drug with the G2/M phase drug results in an unexpectedly greater than additive (i.e., synergistic) apoptosis in multiple myeloma cells. The invention includes methods of treating multiple myeloma by administering the combination of the G1 and/or S phase drug and the G2/M phase drug, pharmaceutical compositions comprising the combination of drugs used in these methods, as well as pharmaceutical kits.
Type:
Grant
Filed:
July 31, 2002
Date of Patent:
July 4, 2006
Assignee:
Dana Farber Cancer Institute, Inc.
Inventors:
Arthur B. Pardee, Kenneth Anderson, Deepak Gupta, Chiang Li, Youzhi Li
Abstract: A coupling element includes a first stage having a dielectric waveguide that is transitioned to a waveguide having a sequence of resonators with a fixed period. A second stage transitions the waveguide to a photonic crystal waveguide by gradually bringing closer at an angle the cladding bulk of the photonic crystal to the waveguide.
Type:
Grant
Filed:
June 18, 2003
Date of Patent:
July 4, 2006
Assignee:
Massachusetts Institute of Technology
Inventors:
Solomon Assefa, Peter Bienstman, Gale S. Petrich, Alexei A. Erchak, Steven G. Johnson, Leslie A. Kolodziejski, John D. Joannopoulos
Abstract: Aryl phosphate derivatives of d4T with para-bromo substitution on the aryl group show markedly increased potency as anti-HIV agents without undesirable levels of cytotoxic activity. In particular, these derivatives are potent inhibitors of HIV reverse transcriptase. In a preferred aspect of the present invention, the phosphorus of the aryl phosphate group is further substituted with an amino acid residue that may be esterified or substituted, such as a methoxy alaninyl group.
Abstract: The invention features a method including: i) confining ions to stable trajectories within an ion trap; ii) exciting a subset of the ions along at least one transverse coordinate; iii) rotating the transverse excitation into an excitation along an axial coordinate; and iv) transferring at least some of the axially excited ions from the ion trap along the axial coordinate. For example, the ions may be transferred to an ion detector or to a subsequent ion trap.